YINGLONG: A Multicenter, Prospective, Non-Interventional Study Evaluating the Safety and Tolerability of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

INTRODUCTION: Ticagrelor is an oral, reversible, direct-acting P2Y(12) receptor inhibitor approved for the prevention of cardiovascular events in acute coronary syndrome (ACS). In China, drug intensive monitoring regulations for new drugs require additional safety data post-approval. METHODS: YINGLO...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xin, Zheng, Yang, Yang, Ping, Ma, Shuren, Yu, Zaixin, Su, Xi, Ge, Junbo, Leonsson-Zachrisson, Maria, Wang, Xianhong, Sun, Jing, Bai, Lu, Ma, Chang-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822841/
https://www.ncbi.nlm.nih.gov/pubmed/31119693
http://dx.doi.org/10.1007/s12325-019-00972-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822841/
https://www.ncbi.nlm.nih.gov/pubmed/31119693
http://dx.doi.org/10.1007/s12325-019-00972-z

Ejemplares similares